Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib in Metastatic Androgen Independent Prostate Cancer
NCT00436956Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2006
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cediranib in prostate cancer (PCa) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival (6-month probability). Started Oct 2006; status: completed.
02
Drugs
cediranib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00436956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436956.